iX Biopharma Income Statement

Financials in millions SGD. Fiscal year is July - June.

Millions SGD. Fiscal year is Jul - Jun.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2016 - 2020
Period Ending	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021	2016 - 2020
Revenue	7.77	5.96	5.91	14.39	1.75	Upgrade
Revenue Growth (YoY)	30.34%	0.78%	-58.91%	724.64%	77.16%	Upgrade
Cost of Revenue	5.73	4.91	3.59	2.1	2.13	Upgrade
Gross Profit	2.04	1.05	2.32	12.29	-0.38	Upgrade
Selling, General & Admin	6.69	6.71	9.04	9.46	8.3	Upgrade
Research & Development	1.64	1.73	2.82	2.33	2.75	Upgrade
Operating Expenses	8.33	8.54	11.86	11.79	11.05	Upgrade
Operating Income	-6.29	-7.5	-9.54	0.5	-11.43	Upgrade
Interest Expense	-0.32	-0.44	-0.27	-0.2	-0.17	Upgrade
Interest & Investment Income	-	0.03	0.01	-	0.01	Upgrade
Currency Exchange Gain (Loss)	-3.4	0.08	-2.77	-1.91	1.8	Upgrade
Other Non Operating Income (Expenses)	-0.13	0.35	1.12	0.74	1.57	Upgrade
EBT Excluding Unusual Items	-10.14	-7.47	-11.46	-0.88	-8.23	Upgrade
Gain (Loss) on Sale of Investments	-0.01	-2.51	1.74	-3.26	-	Upgrade
Other Unusual Items	-	-	0.01	0.04	-	Upgrade
Pretax Income	-10.14	-9.99	-9.71	-4.1	-8.23	Upgrade
Income Tax Expense	0	0.81	-0.09	0.5	0	Upgrade
Earnings From Continuing Operations	-10.14	-10.79	-9.62	-4.6	-8.23	Upgrade
Net Income	-10.14	-10.79	-9.62	-4.6	-8.23	Upgrade
Net Income to Common	-10.14	-10.79	-9.62	-4.6	-8.23	Upgrade
Shares Outstanding (Basic)	877	767	765	746	693	Upgrade
Shares Outstanding (Diluted)	877	767	765	746	693	Upgrade
Shares Change (YoY)	14.25%	0.33%	2.51%	7.60%	7.13%	Upgrade
EPS (Basic)	-0.01	-0.01	-0.01	-0.01	-0.01	Upgrade
EPS (Diluted)	-0.01	-0.01	-0.01	-0.01	-0.01	Upgrade
Free Cash Flow	-3.96	-6.83	-8.36	2.92	-8.91	Upgrade
Free Cash Flow Per Share	-0.01	-0.01	-0.01	0.00	-0.01	Upgrade
Gross Margin	26.27%	17.59%	39.24%	85.41%	-21.89%	Upgrade
Operating Margin	-80.92%	-125.78%	-161.41%	3.48%	-654.96%	Upgrade
Profit Margin	-130.56%	-181.14%	-162.61%	-31.95%	-471.86%	Upgrade
Free Cash Flow Margin	-50.97%	-114.57%	-141.30%	20.31%	-510.32%	Upgrade
EBITDA	-5.87	-7.08	-9.04	1.15	-10.79	Upgrade
EBITDA Margin	-75.54%	-118.88%	-152.93%	7.99%	-	Upgrade
D&A For EBITDA	0.42	0.41	0.5	0.65	0.64	Upgrade
EBIT	-6.29	-7.5	-9.54	0.5	-11.43	Upgrade
EBIT Margin	-80.92%	-125.78%	-161.41%	3.48%	-	Upgrade

Updated Feb 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.